|
Experts discuss Indian pharmaceutical strategic roadmap for 2026
|
|
Shardul Nautiyal, Mumbai
December 29 , 2025
|
|
|
Indian pharmaceutical companies have a golden opportunity to evolve beyond being reliable suppliers to global giants in markets like Europe. They are emerging as trusted innovators delivering meaningful healthcare solutions for India’s future in 2026 and ahead, according to industry experts while discussing a future ready strategic roadmap for the Indian pharma.
Experts further highlight that industry leaders are cutting low-impact projects and investing in AI to drive around 30% of discoveries, while joint government-industry-academia training programs are building a skilled workforce. Global firms are expanding manufacturing, data, and R&D hubs in India, and digital platforms are enabling seamless patient care through telemedicine, AI diagnostics, transparency, and trust.
“To counter pricing pressures like the US Inflation Reduction Act, companies must leverage data swiftly, diversify therapy areas, monitor regulations, foster deeper collaborations, strengthen quality ecosystems, and sustain evidence-based investments for scalable, accessible healthcare,” industry experts recommend.
While talking about major innovation highlights, Nikkhil K. Masurkar, CEO, Entod Pharmaceuticals says that India's 2025 pharma innovations marked a leap forward in patient-centric solutions. Nafithromycin, the nation's first indigenous antibiotic, directly tackles antimicrobial resistance, reducing reliance on imports. Inhaled insulin revolutionized diabetes management with needle-free delivery, enhancing adherence for millions. Regulators approved a world-first unique low-dose atropine eye-drop strength to slow childhood myopia progression, born from local research. India's pioneering presbyopia eye drops addressed age-related near-vision loss non-surgically, expanding options for adults. These breakthroughs underscore the shift from scale to science, blending affordability with cutting-edge R&D.
While discussing patient-centric shifts, industry experts say that India's pharmaceutical landscape in 2025 mirrored global trends while carving its unique path amid rising metabolic diseases. Demand exploded for GLP-1 drugs targeting obesity and diabetes, with the market surging to USD 110-115 million in 2024 at a 27-34% CAGR through 2030, fuelled by nearly 100 million diabetes cases and generics. Companies also expanded into cardiovascular, neurological, and chronic care segments with high unmet needs, complementing metabolic disorder focus.
“Biotech firms staged a strong recovery through strategic M&A deals, bolstered by PLI incentives and funding rebounds, though oncology therapies delivered mixed results amid high expectations, pricing pressures, and competition for affordable options. The key lesson from these shifts: Personalization builds lasting loyalty, with AI-powered platforms driving sales uplifts through targeted engagement. Heading into 2026, companies must embrace multi-channel strategies: digital apps, community outreach, and localized support to connect effectively, especially in fast-growing emerging markets like India,” experts conclude.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|